Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study / Efeito da espironolactona na progressão da calcificação coronariana em pacientes em diálise peritoneal: um estudo piloto

ABSTRACT Introduction: There is evidence that aldosterone plays a role in the pathogenesis of vascular calcification. The aim of this study was to evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, on the progression of coronary calcification (CC) in peritoneal dialysis patients and to identify the factors involved in this progression. Methods: Thirty-three patients with a coronary calcium score (CCS) ≥ 30, detected through multi-detector computed tomography (MDCT) and expressed in Agatston units, were randomly assigned to a group receiving 25mg spironolactone per day for 12 months (spironolactone group) and a control group not receiving this drug. The primary outcome was a percentage change in CCS from baseline to end of the study (relative progression), when a further MDCT was conducted. Patients who had progression of CC were compared with those who did not progress. Results: Sixteen patients, seven in the spironolactone group and nine in the control group, concluded the study. The relative progression of the CCS was similar in both groups, 17.2% and 27.5% in the spironolactone and control groups respectively. Fifty-seven percent of the treated patients and 67% of those in the control group presented progression in the CC scores (p = 0.697). Progressor patients differed from non-progressors because they presented higher levels of calcium and low-density lipoprotein cholesterol and lower levels of albumin. Conclusion: In peritoneal dialysis patients, spironolactone did not attenuate the progression of CC. However, large-scale studies are needed to confirm this observation. Disorders of mineral metabolism and dyslipidemia are involved in the progression of CC.

RESUMO Introdução: Existem evidências de que a aldosterona exerça um papel na patogênese da calcificação vascular. O objetivo deste estudo foi avaliar o efeito da espironolactona, um antagonista do receptor mineralocorticoide, na progressão da calcificação coronariana (CC) de pacientes em diálise peritoneal, e identificar os fatores envolvidos nessa progressão. Métodos: Trinta e três pacientes com escore de cálcio coronariano (ECC) ≥ 30, detectado por tomografia computadorizada com múltiplos detectores (TCMD) e expresso em unidades de Agatston, foram randomizados para um grupo que recebeu 25 mg de espironolactona por dia durante 12 meses (grupo espironolactona) e um grupo controle que não recebeu este medicamento. O desfecho primário foi a mudança percentual do ECC do início para o final do estudo (progressão relativa), quando uma nova TCMD foi realizada. Os pacientes que tiveram progressão de CC foram comparados com aqueles que não progrediram. Resultados: Dezesseis pacientes, sete no grupo espironolactona e nove no grupo controle, concluíram o estudo. A progressão relativa do ECC foi semelhante nos dois grupos, 17,2% e 27,5% nos grupos espironolactona e controle, respectivamente. Cinquenta e sete por cento dos pacientes tratados e 67% daqueles no grupo controle apresentaram progressão nos escores de CC (p = 0,697). Os pacientes progressores diferiram dos não progressores porque apresentaram níveis séricos mais elevados de cálcio e LDL-colesterol e menores níveis de albumina. Conclusão: Em pacientes em diálise peritoneal, a espironolactona não atenuou a progressão da CC. No entanto, estudos em grande escala são necessários para confirmar essa observação. Distúrbios do metabolismo mineral e dislipidemia estão envolvidos na progressão da CC.

Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study.

INTRODUCTION: There is evidence that aldosterone plays a role in the pathogenesis of vascular calcification. The aim of this study was to evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, on the progression of coronary calcification (CC) in peritoneal dialysis patients and to identify the factors involved in this progression. METHODS: Thirty-three patients with a coronary calcium score (CCS) ≥ 30, detected through multi-detector computed tomography (MDCT) and expressed in Agatston units, were randomly assigned to a group receiving 25mg spironolactone per day for 12 months (spironolactone group) and a control group not receiving this drug. The primary outcome was a percentage change in CCS from baseline to end of the study (relative progression), when a further MDCT was conducted. Patients who had progression of CC were compared with those who did not progress. RESULTS: Sixteen patients, seven in the spironolactone group and nine in the control group, concluded the study. The relative progression of the CCS was similar in both groups, 17.2% and 27.5% in the spironolactone and control groups respectively. Fifty-seven percent of the treated patients and 67% of those in the control group presented progression in the CC scores (p = 0.697). Progressor patients differed from non-progressors because they presented higher levels of calcium and low-density lipoprotein cholesterol and lower levels of albumin. CONCLUSION: In peritoneal dialysis patients, spironolactone did not attenuate the progression of CC. However, large-scale studies are needed to confirm this observation. Disorders of mineral metabolism and dyslipidemia are involved in the progression of CC.

Cardiac evaluation of patients with chronic kidney disease: what lessons?

INTRODUCTION: Patients with chronic kidney disease (CKD) experiment a synergistic effect of the traditional and the emerging uremia-related risk factors for atherosclerosis. OBJECTIVE: Draw the epidemiologic profile of a group of CKD patients who underwent cardiac evaluation. METHODS: Symptomatic patients, patients with ischemia on myocardial scintigraphy and/or systolic dysfunction on echocardiography, patients older than 50 years and diabetes mellitus (DM) as a cause of CKD, and those with two or more risk factors underwent coronary angiography. Asymptomatic, non-diabetic patients and patients with no risk factors were investigated with echocardiography. Those with a single risk factor were investigated with echocardiography and scintigraphy. RESULTS: 46 patients (58.7% men) were enrolled. Their mean age was 50.7 ± 11.7 years. 91.3% were on dialysis, for 61.96 ± 55.1 months. Hypertension was the cause of CKD in 56.5%. Of the 28 patients (60.9%) who underwent angiography, 53.6% had coronary artery disease (CAD). The patients were divided into three groups: those with CAD (A), those without CAD (B) and those who didn't undergo coronary angiography (C). A significant difference occurred only between groups B and C, as regards an abnormal ABI (p = 0.026), with no ABI abnormality in group C, and as regards the mean age, which was higher in group B (p = 0.045). In group A, 53.3% of the patients were in the preoperative stage of parathyroidectomy. CONCLUSION: This study confirmed the high rate of cardiovascular disorders, including CAD, in patients with CKD, especially those on dialysis.

Avaliação cardiológica de pacientes portadores de doença renal crônica: quais as lições? / Cardiac evaluation of patients with chronic kidney disease: what lessons?

INTRODUÇÃO: Pacientes com doença renal crônica (DRC) apresentam sinergismo entre fatores de risco tradicionais para aterosclerose e emergentes derivados do estado urêmico. OBJETIVO: Traçar o perfil epidemiológico de um grupo de pacientes com DRC submetido à avaliação cardiológica. MÉTODOS: Pacientes sintomáticos - com isquemia em cintilografia miocárdica e/ou disfunção sistólica ao ecodopplercardiograma - com idade maior que 50 anos e diabetes mellitus (DM) como causa da DRC e aqueles com dois ou mais fatores de risco ateroscleróticos realizaram cineangiocoronariografia. Assintomáticos - não diabéticos e sem fatores de risco - foram investigados com ecodopplercardiograma e aqueles com único fator de risco, por meio de ecodopplercardiograma e cintilografia. RESULTADOS: Foram estudados 46 pacientes, 58,7% homens, idade de 50-70 ± 11,7 anos, 91,3% dialíticos. Tempo de hemodiálise: 61,96 ± 55,1 meses. Hipertensão arterial foi causa da DRC em 56,5%. Dos 28 pacientes (60,9%) submetidos à cineangiocoronariografia, 53,6% apresentaram doença arterial coronariana (DAC). Os pacientes foram divididos em três grupos: com DAC (A), sem DAC (B) e não submetidos à cineangiocoronariografia (C). Diferença significativa ocorreu entre os Grupos B e C na frequência de índice tibiobraquial (ITB) anormal (p = 0,026), com ausência de ITB anormal no Grupo C e na média de idade, superior no B (p = 0,045). No Grupo A, 53,3% dos pacientes estavam em avaliação pré-paratireoidectomia (PTX). CONCLUSÃO: Este estudo confirmou a alta frequência de alterações cardiovasculares, inclusive de DAC, nos pacientes portadores de DRC, principalmente naqueles em diálise.

INTRODUCTION: Patients with chronic kidney disease (CKD) experiment a synergistic effect of the traditional and the emerging uremia-related risk factors for atherosclerosis. OBJECTIVE: Draw the epidemiologic profile of a group of CKD patients who underwent cardiac evaluation. METHODS: Symptomatic patients, patients with ischemia on myocardial scintigraphy and/or systolic dysfunction on echocardiography, patients older than 50 years and diabetes mellitus (DM) as a cause of CKD, and those with two or more risk factors underwent coronary angiography. Asymptomatic, non-diabetic patients and patients with no risk factors were investigated with echocardiography. Those with a single risk factor were investigated with echocardiography and scintigraphy. RESULTS: 46 patients (58.7% men) were enrolled. Their mean age was 50.7 ± 11.7 years. 91.3% were on dialysis, for 61.96 ± 55.1 months. Hypertension was the cause of CKD in 56.5%. Of the 28 patients (60.9%) who underwent angiography, 53.6% had coronary artery disease (CAD). The patients were divided into three groups: those with CAD (A), those without CAD (B) and those who didn't undergo coronary angiography (C). A significant difference occurred only between groups B and C, as regards an abnormal ABI (p = 0.026), with no ABI abnormality in group C, and as regards the mean age, which was higher in group B (p = 0.045). In group A, 53.3% of the patients were in the preoperative stage of parathyroidectomy. CONCLUSION: This study confirmed the high rate of cardiovascular disorders, including CAD, in patients with CKD, especially those on dialysis.

Paratireoidectomia guiada por fluorescência - nova técnica cirúrgica para tratamento do hiperparatireoidismo secundário / Fluorescence guided parathyroidectomy - a new surgical technique for secondary hyperparathyroidism

Objetivo: Apresentar a técnica de fotossensibilização efluorescência para paratireoidectomia no tratamento doHiperparatireoidismo secundário. Relatar casos submetidosa esta técnica. Discutir aplicações e limitações. Pacientese Método: Paciente 1. MJSM, sexo feminino, 57 anos, comInsuficiência renal crônica por tuberculose renal e em programade hemodiálise há 8 anos. Portadora de Hepatite C. Paciente 2.PSF, sexo masculino, 21 anos com história de Insuficiência renalcrônica de etiologia indeterminada em hemodiálise há 7 anos.Paciente 3. JVM 57 anos, sexo masculino, em programa dehemodiálise há 10 anos por Insuficiência renal crônica secundáriaa Hipertensão arterial. Submetido a dois procedimentos cirúrgicospara tratamento de hiperparatireoidismo secundário semsucesso. Administração de ácido 5-aminolevulínico hidroclorado(5ALA) 30mg/kg (Fluka®) por via oral diluído em água 4 horasantes do procedimento cirúrgico. Observação da topografia dasparatireoides sob condições luminosas normais e com o usoda fonte de luz com filtro específico (360-440 nm) acoplado.Resultados: Todas as glândulas paratireoides foram claramenteidentificadas após a exposição do campo cirúrgico com a luz deexcitação azul. A resposta induzida pela administração do 5ALAconsiste de uma típica luz fluorescente vermelha - 635 nm. Asestruturas circunvizinhas como tireoide e gânglios linfáticospermaneceram não fluorescentes. A análise histológica mostrouhiperplasia paratireoidea em todos os tecidos fluorescenteremovidos. O paratormônio pós-operatório no 15º dia era de 43no primeiro paciente, 51 no segundo e 57 no terceiro. Conclusão:A técnica de fluorescência para paratireoidectomia é de fácilaplicação metodológica e foi eficaz na detecção das paratireoideshiperplasiadas.

Objective: To present the photosensitization and fluorescenceguided parathyroidectomy in the treatment of the secondaryhyperparathyroidism. Report the cases. Discuss its applicationsand limitations. Patients and Method: Patient 1. MJSM, 57 yearold female with chronic renal insufficient from a renal tuberculosisand hemodialytic treatment since 8 years. She had serology testpositive for hepatitis C virus. Patient 2. PSF, 21 year old malewith a chronic renal insufficiency from a non-determined etiologyand hemodialytic treatment since 7 years. Patient 3. JVM 57year old male with renal failure and hemodialytic treatment since1998 secondary to arterial hypertension. He was submitted atwo surgical procedures without success. Oral administration of5-aminolevulinc acid hydrochloride (5ALA) 30mg/Kg (Fluka®) 4hours before the surgery. Observation of the parathyroid?s siteswith normal light conditions and with a specific light filter (360-440nm). Results: All parathyroids glands were clearly identifiedafter the blue light exposition. The response induced by 5ALAadministration is a typical fluorescent red light- 635 nm. Theadjacent structures as thyroid and lymph nodes remained nonfluorescents.The histological analysis showed parathyroidhyperplasia in all removed fluorescent tissues. The parathormonepost-surgical in the 15th day were 43 in the first patient, 52 in thesecond, and 57 in the third. Conclusion: The fluorescence guidedparathyroidectomy is easy to apply and was efficient to detect theparathyroids with hyperplasia.

Efeito benéfico da correção da acidose metabólica no estado nutricional de pacientes em hemodiálise / Beneficial effects of metabolic acidosis correction in hemodialysis patients

Objetivo: Avaliar o efeito da correção da acidose metabólica no estado nutricional de pacientes em hemodiálise. Métodos: Foram estudados, durante seis meses, 20 pacientes com acidose metabólica, definida pela média de tr~es mensurações de bicarbonato sérico pré-diálise <22 mEq/L. os pacientes dialisavam há, pelo menos, seis meses, utilizando bicarbonato de 35 mEq/L no dialisato. A correção da acidose metabólica foi feita mediante elevação do bicarbonato no dialisato para valores que não ultrapassaram 40 mEq/L, objetivando um bicarbonato sérico entre 22-26 mEq/L. Foram avaliados no início e no final do estudo: avaliação antropométrica, dietética, bioquímica e Avaliação subjetiva Global (ASG). Resultados: A avaliação nutricional na fase inicial do estudo demonstrou índice de massa corporal normal (24,23 +- 3,83 Kg/m²). A circunferência muscular do braço, a prega cutânea tricipital e a ASG classificaram homens e mulheres como desnutridos. Os consumos de calorias e proteínas foram 29,7 +- 10,1 Kcal?kg/dia e 1,31 +- 0,35 g/Kg/dia, respectivamente. A avaliação bioquímica observou albumina sérica normal e colesterol reduzido. Após correção, bicarbonato sérico e pH aumentaram de 18,2 +- 1,64 para 22 +- 1,70 (p<0,001), e de 7,32+- 0,45 para 7,37 +-0,41 (p<0,001), respectivamente. Houve melhora da ASG (21,7 +- 6,4 versus 16,8 +-6,6, p<0,0001) e aumento na ingestão calórica (1.892,61 +-454,30 versus 2.110,30 +-869,24, p<0,05). Conclusão: A suplementação de bicarbonato na solução de hemodiálise foi método efetivo para a correção da acidose metabólica, determinando aumento da ingestão calórica e melhora nos escores da ASG.

Objective: To evaluate the effect of correction of metabolic acidosis on nutritional status of hemodialysis patients. Methods: We studied for six months, 20 patients with metabolic acidosis, defined as the average of tr ~ s measurements of predialysis serum bicarbonate <22 mEq / L. patients receiving dialysis treatment for at least six months, using bicarbonate of 35 mEq / L in the dialysate. The correction of metabolic acidosis was observed in the high bicarbonate dialysate for values that exceeded 40 mEq / L, aiming for a serum bicarbonate between 22-26 mEq / L. Were assessed at baseline and at the end of the study: anthropometric, dietary, biochemical and Subjective Global Assessment (SGA). Results: The nutritional assessment in the initial phase of the study showed normal BMI (24.23 + - 3.83 kg / m²). The arm muscle circumference, triceps skinfold and the ASG men and women classified as malnourished. The intake of calories and protein were 29.7 + - 10.1 Kcal? Kg / day and 1.31 + - 0.35 g / kg / day, respectively. The biochemical evaluation showed normal serum albumin and low cholesterol. After correction, serum bicarbonate and pH increased from 18.2 + - 1.64 for 22 + - 1.70 (p <0.001), and 7.32 + - 0.45 to 7.37 + -0.41 ( p <0.001), respectively. There was improvement in ASG (21.7 + - 6.4 versus 16.8 + -6.6, p <0.0001) and increased caloric intake (1892.61 + -454.30 vs 2110.30 + -869 , 24, p <0.05). Conclusion: Supplementation of bicarbonate in the dialysis solution was an effective method for correction of metabolic acidosis, determining increased caloric intake and improvement in the scores of the ASG.